Report

The CRISPR Technology Market size is estimated at USD 4.53 billion in 2025, and is expected to reach USD 11.23 billion by 2030, at a CAGR of 19.89% during the forecast period (2025-2030).

Factors driving the global market's growth include increasing government and private funding, rising demand for and adoption of CRISPR, and technological advancements.

The growing funding and support activities by the government and private entities, along with the launch of various research projects and programs, are expected to advance CRISPR technology over time. This substantial financial backing is anticipated to enhance the market prospects for CRISPR technology. For instance, in July 2023, Pfizer invested USD 25 million in Caribou Sciences, giving the company a boost of funding for an experimental multiple myeloma treatment. The investment agreement directs Caribou to use the funds to advance CB-011. This CRISPR-edited allogeneic CAR T-cell therapy is currently in Phase 1 testing for patients with relapsed or refractory multiple myeloma.

There has also been a rise in research projects and program grants in the CRISPR domain. For instance, in October 2023, Yale School of Medicine received a grant of USD 40 million from the National Institutes of Health (NIH) for its research on developing a CRISPR gene-editing platform technology capable of reaching the human brain. The innovative new genome-editing technology could lead to treatments or cures for many neurogenetic diseases. Such funding for market players and grants from national institutes are expected to help boost the CRISPR technology market over the forecast period.

Additionally, CRISPR technology advances genome editing across the fields of medicine, biotechnology, and agriculture, enabling scientists to conduct research through faster and more efficient genome editing. For instance, according to a report published by Nature Publications in November 2022, CRISPR gene editing can alter patients' immune cells (T cells) to recognize disease-causing proteins expressed in solid tumors. This work builds on research on genome editing to redirect T?cell specificity with transgenic TCR engineering. Thus, owing to its easy, quick, and inexpensive access to vectors and the resulting next-generation tools, the demand for CRISPR technology is expected to increase over the forecast period.

CRISPR-Cas9 works by precisely editing the DNA within cells, allowing researchers to correct genetic mutations associated with inherited eye diseases, neurodegenerative conditions like Alzheimer's and Huntington's, and even non-inherited diseases such as cancer and HIV. By targeting and modifying specific genes implicated in these diseases, CRISPR holds promise for potentially treating or preventing diseases at their genetic roots. For instance, according to the study published by Springer Nature in March 2023, the rapid development of CRISPR-based genome editing technology emphasizes the expansion of the CRISPR-Cas toolbox with novel Cas orthologs, engineered variants, and transposon-associated programmable RNA-guided systems.

The abovementioned report also discussed the potential applications of CRISPR-Cas systems in precise genome editing, such as base editing and prime editing, and their revolutionary impact on cardiovascular research. CRISPR-Cas systems have been demonstrated in creating genetically modified in vitro and animal models of cardiovascular diseases, which offer valuable insights into the genetic basis of cardiovascular conditions and potential avenues for therapeutic interventions. Thus, the market studied is projected to record growth over the forecast period in line with increasing government and private funding, rising demand for and adoption of CRISPR, and technological advancements. However, the high costs of CRISPR and ethical concerns related to genetic research are restraining the growth of the market.

CRISPR Technology Market Trends

The Biomedical Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Applications in the biomedical segment are expected to grow at a significant rate over the forecast period due to the increased usage of CRISPR technology and growing research activities. The segment involves genome engineering, disease model studies, functional genomics, and epigenetics. The CRISPR/Cas9 system is broadly and successfully applied for biomedical discoveries in several areas, particularly sensing nucleic-acid-based biomarkers of infectious and non-infectious diseases and detecting mutations and deletions indicative of genetic diseases.

There has been a notable surge in research and development efforts surrounding CRISPR technology and its utilization within biological systems. For instance, according to a report published by the Diagnostics Journal in October 2022, the CRISPR/CRISPR-associated protein (Cas) system is a sensitive and specific biological system that can quickly identify pathogen-specific nucleic acids. The CRISPR/Cas system has also shown excellent performance in developing pathogen nucleic acid-detection technology. Researchers have made many rapid, convenient, and feasible innovations in pathogen nucleic acid detection technology in combination with various biosensing technologies. The significant adoption of CRISPR gene editing tools across various biomedical applications is contributing to the growth of this segment.

Additionally, introducing nano-carriers and improved delivery systems have enhanced the efficacy and specificity of this technology. Hence, it is increasingly adopted in gene and cell therapy as well as regenerative medicine. For instance, according to a report published by Molecular Cancer in March 2022, CRISPR-Cas9 technology has experienced a notable increase in utilizing genome editing approaches to address diverse genetic disorders and cancers. This involves the correction of known gene mutations associated with inherited genetic diseases. Hence, the widespread adoption of CRISPR/Cas9 technology, facilitated by its easy and precise genome editing capabilities, coupled with advancements in nano-carriers and delivery systems, is driving its increased applications in gene and cell therapy as well as various biomedical sciences, particularly in regenerative medicine and cancer immunotherapy.

Moreover, CRISPR technology exhibits therapeutic applications such as treating genetic disorders, discovering drugs, and identifying cancer biomarkers. These versatile therapeutic functionalities contribute to the technology's broad utility and potential impact across various professional and medical segments. For instance, in February 2023, the American Chemical Society's researchers developed a non-invasive and easy-to-use method for cancer diagnosis using blood samples. The process involves detecting cancer-related molecules in exosomes, small vesicles released by cells found in plasma. Exosomes carry biomarkers, such as microRNAs (miRNAs), which can reflect the condition of the originating cell, especially cancerous cells.

Thus, the biomedical segment is anticipated to grow significantly over the forecast period due to increased applications of CRISPR technology in the biomedical segment.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

The CRISPR technology market in North America is expected to grow significantly during the study period due to technological innovations, product approvals, critical initiatives by market players, and the technology's multiple advantages.

Major companies in the market are initiating research and introducing new products to cater to the rising demand for CRISPR systems. For instance, in March 2023, Synthego Corporation launched its service partner ecosystem, CRISPR Discovery Partners, which is designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services. The ecosystem brings together high-value partners, including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx, to offer a coordinated solution for CRISPR-driven drug discovery.

Furthermore, competition among the existing market players has increased due to technological developments and the potential applications of CRISPR technology in various fields. There is an increased focus on this highly adaptable technology. This competition also encourages companies to adopt strategies like acquisition and mergers. For instance, in February 2023, Sherlock Biosciences completed the acquisition of Sense Biodetection (Sense). This acquisition accelerates Sherlock�s ability to conveniently put the most advanced CRISPR-based diagnostics in the hands of global consumers.

Major players are investing in establishing new research laboratories and production facilities to augment CRISPR systems' research and production capabilities. This proactive approach aims to create enhanced opportunities for CRISPR technologies within the market. For instance, in May 2023, Synthego Corporation opened its new good manufacturing practice (GMP) synthesis facility. This 18,000 sq. ft facility supports the growing demand for developing high-quality, clustered, regularly interspaced short palindromic repeats (CRISPR)-enabled in-vivo and ex-vivo therapeutics. The facility also includes research services for investigational new drugs, new drug applications, and biologics license applications enabling clinical studies.

Thus, the growth of the CRISPR market in North America is propelled by technological innovations, product approvals, strategic initiatives by market players, increased competition driving research and development, and significant investments in research facilities and production capabilities to meet the rising demand for CRISPR technologies.

CRISPR Technology Industry Overview

The CRISPR technology market is moderately fragmented and competitive, with several major players. The rising focus of companies on personalized medicine, co-development activities, and increased cases of adverse drug reactions are expected to boost the competitive nature of the market studied. Companies like ThermoFisher Scientific Inc., Merck KGaA, GenScript, Danaher Corporation (Integrated DNA Technologies (IDT)), and PerkinElmer Inc. hold a substantial share in the market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format


• 3 months of analyst support